Thrivent Financial for Lutherans Acquires 3,602 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Thrivent Financial for Lutherans boosted its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 16.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 25,408 shares of the company’s stock after buying an additional 3,602 shares during the quarter. Thrivent Financial for Lutherans’ holdings in GE HealthCare Technologies were worth $2,385,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pathway Financial Advisers LLC bought a new stake in GE HealthCare Technologies during the 1st quarter worth about $25,000. LGT Financial Advisors LLC raised its holdings in GE HealthCare Technologies by 1,673.3% during the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the last quarter. Fred Alger Management LLC bought a new stake in GE HealthCare Technologies during the 2nd quarter worth about $26,000. Capital Performance Advisors LLP bought a new stake in GE HealthCare Technologies during the 3rd quarter worth about $26,000. Finally, Ashton Thomas Securities LLC acquired a new position in shares of GE HealthCare Technologies during the 3rd quarter worth about $26,000. 82.06% of the stock is owned by institutional investors.

GE HealthCare Technologies Stock Up 0.6 %

GEHC opened at $83.00 on Thursday. GE HealthCare Technologies Inc. has a 1-year low of $66.39 and a 1-year high of $94.55. The stock’s fifty day simple moving average is $88.19 and its 200 day simple moving average is $83.61. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. The stock has a market cap of $37.92 billion, a PE ratio of 22.82, a price-to-earnings-growth ratio of 2.96 and a beta of 1.24.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The business had revenue of $4.86 billion for the quarter, compared to analysts’ expectations of $4.87 billion. During the same quarter in the prior year, the business earned $0.99 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. As a group, research analysts expect that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be issued a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies’s dividend payout ratio is currently 3.30%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Evercore ISI boosted their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Redburn Atlantic upgraded GE HealthCare Technologies to a “strong-buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company boosted their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. initiated coverage on GE HealthCare Technologies in a research report on Monday, September 9th. They set a “neutral” rating and a $90.00 target price for the company. Finally, BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.36.

Insider Buying and Selling at GE HealthCare Technologies

In other news, CEO Roland Rott sold 3,577 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the sale, the chief executive officer now directly owns 24,298 shares of the company’s stock, valued at approximately $2,101,291.04. This represents a 12.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.